ESMO 2025 – Boehringer and Bayer eye the front line
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
J&J claims a Tecvayli/Darzalex combo win
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
Petosemtamab shows first colorectal promise
But more detail is awaited, especially on toxicity.
ESMO 2025 preview – first clinical results
The ESMO regular abstract lift reveals first human datasets for several projects.
ESMO 2025 preview – Astellas's third Claudin18.2 shot
Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.
ESMO 2025 preview – Sanofi’s lead shot gets a boost
The group toplines a phase 2 win with Alphamedix.
ESMO 2025 preview – Astra and Daiichi keep abreast of Gilead
Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.
